Atherogenics, Inc.

Salutria Pharmaceuticals LLC

Ahterogenics, Inc.

Charles Q Meng

James A Sikorski

M David Weingarten

Liming Ni

Lee K Hoong

Uday Saxena

Jayraz Luchoomun

Kimberly J Worsencroft

Patricia K Somers

Raymond A Ng

Zhihong Ye

Wei Zhang

Jacob E Simpson

Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof: wherein:

Sulfonamide containing compounds for treatment of inflammatory disorders

This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.

Compounds and method for the inhibition of the expression of VCAM-1

Organic amine salts of compounds of the formula: and their pharmaceutically acceptable salts, and uses in medical therapy are provided.

Salt forms of poorly soluble probucol esters and ethers

The invention relates to compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds, wherein the compounds are of the following Formulas: or a pharmaceutically acceptable salt, ester or prodrug thereof, wherein the substituents are defined in the application. The invention further provides methods of treatment of inflammatory disorders by administering the compounds.

Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease

The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.

1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders

It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.

Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality

Sulfonamide-substituted chalcone derivatives and their use to treat diseases

Chalcone derivatives and their use to treat diseases

It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inflammatory disorders that are mediated by VCAM-1 include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.

1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders

Organic amine salts of compounds of the formula:and their pharmaceutically acceptable salts, and uses in medical therapy are provided.

Thioketals and thioethers are provided that inhibit the expression of VCAM-1, and which can be used in the treatment of VCAM-1 mediated diseases including inflammatory disorders, cardiovascular diseases, occular diseases, autoimmune diseases, neurological disorders, and cancer. The compounds also can be used to treat hyperlipidemia and/or hypercholesterolemia.

Growing community of inventors

Alpharetta, GA, United States of America

Charles Q Meng